Add-on of basal insulin (BI) to intensify the ongoing therapy with glucagon-like peptide 1 receptor agonist (GLP-1 RA) is recommended, but it is unclear if free or fixed combination of BI and GLP-1 RA produce similar outcomes. A retrospective comparative effectiveness analysis of the add-on of glargine 300 U/mL (Gla-300) to ongoing GLP-1 RA vs. switch to fixed ratio combination of degludec and liraglutide (IDegLira) was performed. Real-world data collected in electronic medical records by 32 Italian diabetes clinics. Propensity score (PS) adjustment was applied to assess changes in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), body weight, and BI dose after 6 months from Gla-300 or IDegLira initiation. Although inertia in insulin initiation and titration was documented in both groups, higher benefit on FBG control was obtained with free vs. fixed combination, likely due to a better titration of BI and GLP-1 RA.

中文翻译：

---

2 型糖尿病中胰高血糖素样肽 1 受体激动剂后的治疗强化：GLP-1 RA 和基础胰岛素的自由组合与固定组合之间的比较有效性分析。 RESTORE-G 现实世界研究

建议添加基础胰岛素 (BI) 以强化胰高血糖素样肽 1 受体激动剂 (GLP-1 RA) 的持续治疗，但尚不清楚 BI 和 GLP-1 RA 的自由或固定组合是否会产生类似的结果。对正在进行的 GLP-1 RA 中添加甘精胰岛素 300 U/mL (Gla-300) 与改用固定比例德谷得和利拉鲁肽组合 (IDegLira) 进行回顾性比较有效性分析。 32 家意大利糖尿病诊所在电子病历中收集的真实世界数据。倾向评分 (PS) 调整用于评估 Gla-300 或 IDegLira 开始 6 个月后糖化血红蛋白 (HbA1c)、空腹血糖 (FBG)、体重和 BI 剂量的变化。尽管两组都记录了胰岛素起始和滴定的惰性，但与固定组合相比，自由组合在 FBG 控制方面获得了更高的益处，这可能是由于 BI 和 GLP-1 RA 的滴定更好。